Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
J Urol. 2022 Dec;208(6):1226-1239. doi: 10.1097/JU.0000000000002902. Epub 2022 Aug 25.
Data comparing radical prostatectomy and external beam radiation therapy with low dose rate brachytherapy boost are lacking. To better guide shared decision making regarding treatment, we compared patient reported outcomes through 5 years following radical prostatectomy or external beam radiation therapy with low dose rate brachytherapy boost for localized prostate cancer.
From 2011-2012, men aged <80 years with localized prostate adenocarcinoma were enrolled and followed longitudinally. Patient reported outcomes included the Expanded Prostate Index Composite. Regression models adjusted for baseline scores and covariates were constructed.
The study population included 112 men treated with external beam radiation therapy with low dose rate brachytherapy boost and 1,553 treated with radical prostatectomy. Compared to radical prostatectomy, external beam radiation therapy with low dose rate brachytherapy boost was associated with clinically meaningful worse urinary irritative/obstructive (adjusted mean score difference [95% confidence interval]: 5.0 [-8.7, -1.3]; 008 at 5 years) and better urinary incontinence function (13.3 [7.7, 18.9]; 001 at 5 years) through 5 years. Urinary function bother was similar between groups (4 at all timepoints). Treatment with external beam radiation therapy with low dose rate brachytherapy boost was associated with worse bowel function (-4.0 [-6.9, -1.1]; 006 at 5 years) through 5 years compared to radical prostatectomy. Treatment with external beam radiation therapy with low dose rate brachytherapy boost was associated with better sexual function at 1 year (12.0 [6.5, 17.5]; 001 at 1 year) compared to radical prostatectomy, but there was insufficient evidence to reject the supposition that no difference was seen at 3 or 5 years.
Compared to radical prostatectomy, external beam radiation therapy with low dose rate brachytherapy boost was associated with clinically meaningful worse urinary irritative/obstructive and bowel functions but better urinary incontinence function through 5 years after treatment. These patient-reported functional outcomes may clarify treatment expectations and help inform treatment choices for localized prostate cancer.
缺乏根治性前列腺切除术和低剂量率近距离放射治疗联合外照射放疗与单纯外照射放疗比较的资料。为了更好地指导治疗决策,我们比较了局限性前列腺癌患者接受根治性前列腺切除术或低剂量率近距离放射治疗联合外照射放疗 5 年后的患者报告结局。
2011 年至 2012 年,我们招募了年龄<80 岁的局限性前列腺腺癌患者,并进行了纵向随访。患者报告结局包括扩展前列腺指数综合评分。构建了调整基线评分和协变量的回归模型。
研究人群包括 112 例接受低剂量率近距离放射治疗联合外照射放疗的患者和 1553 例接受根治性前列腺切除术的患者。与根治性前列腺切除术相比,低剂量率近距离放射治疗联合外照射放疗在治疗后 5 年内具有更明显的尿刺激/梗阻(调整后平均评分差异[95%置信区间]:5.0[−8.7,−1.3];0.08 分)和更好的尿失禁功能(13.3[7.7,18.9];0.01 分)。两组患者的尿功能困扰程度相似(各时间点均为 4 分)。与根治性前列腺切除术相比,低剂量率近距离放射治疗联合外照射放疗在治疗后 5 年内具有更明显的肠道功能障碍(−4.0[−6.9,−1.1];0.06 分)。与根治性前列腺切除术相比,低剂量率近距离放射治疗联合外照射放疗在治疗后 1 年时具有更好的性功能(12.0[6.5,17.5];0.01 分),但没有足够的证据否定在 3 年或 5 年时没有差异的假设。
与根治性前列腺切除术相比,低剂量率近距离放射治疗联合外照射放疗在治疗后 5 年内具有更明显的尿刺激/梗阻和肠道功能障碍,但具有更好的尿失禁功能。这些患者报告的功能结局可能阐明了治疗预期,并有助于为局限性前列腺癌的治疗选择提供信息。